Silvia Catanese
YOU?
Author Swipe
View article: Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer
Abdominal Visceral-to-Subcutaneous Fat Volume Ratio Predicts Survival and Response to First-Line Palliative Chemotherapy in Patients with Advanced Gastric Cancer Open
Prognosis in advanced gastric cancer (aGC) is predicted by clinical factors, such as stage, performance status, metastasis location, and the neutrophil-to-lymphocyte ratio. However, the role of body composition and sarcopenia in aGC surviv…
View article: P-54 Circulating immune cells as a tool to predict benefit from atezolizumab/bevacizumab in advanced hepatocellular carcinoma (aHCC)
P-54 Circulating immune cells as a tool to predict benefit from atezolizumab/bevacizumab in advanced hepatocellular carcinoma (aHCC) Open
View article: Correction to: Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies
Correction to: Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies Open
View article: Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study
Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study Open
Background FLOT regimen is the standard perioperative treatment in Western countries for patients with locally advanced gastric (GC) or gastroesophageal junction cancer (GEJC). High microsatellite instability (MSI-H) and Mismatch Repair de…
View article: Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies
Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies Open
Background Cancer patients are more vulnerable to COVID-19 and are thus given high priority in vaccination campaigns. In solid cancer patients treated with checkpoint inhibitors, we evaluated the amount of anti-RBD and neutralizing antibod…
View article: Supplementary Material for: Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy
Supplementary Material for: Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy Open
Introduction: In locally advanced gastric cancer (GC), FLOT represents the standard perioperative regimen and combination with immunotherapy is under investigation. However, the role of immune tumor microenvironment (TME) is poorly recogni…
View article: Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer.
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer. Open
Ramucirumab plus paclitaxel is considered the standard of care in the second-line treatment of gastric carcinoma (GC). The aim of this study was to evaluate plasma vascular endothelial growth factor-A (VEGF-A), VEGF-D, and circulating solu…
View article: Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy Open
Our study highlighted for the first time the efficacy and safety of lenvatinib in an Italian cohort of patients.
View article: Biomarkers related to fatty acid oxidative capacity are predictive for continued weight loss in cachectic cancer patients
Biomarkers related to fatty acid oxidative capacity are predictive for continued weight loss in cachectic cancer patients Open
Background Cachexia is characterized by a negative protein and energy balance leading to loss of adipose tissue and muscle mass. Cancer cachexia negatively impacts treatment tolerability and prognosis. Supportive interventions should be in…
View article: Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer
Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is a non-immunogenic tumor poorly responsive to immune checkpoint inhibitors. This study investigates the effect of 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (FOLFIRINOX), and gemcitabine pl…
View article: In Reply
In Reply Open
This letter to the editor responds to comments by Hori et al. on the recently published study on intrahepatic cholangiocarcinoma and HER2 positivity rate.
View article: Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis Open
View article: Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients
Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients Open
Sarcopenia is recognised as a predictor of toxicity and survival in localised and locally advanced gastric cancer (GC). Its prognostication power in advanced unresectable or metastatic GC (aGC) is debated. The survival impact of visceral a…
View article: Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?
Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind? Open
View article: HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer
HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer Open
Background HER2 overexpression has been investigated as a potential biomarker and therapeutic target in biliary tract cancer (BTC), but a prognostic role of such alteration has not been demonstrated yet. Materials and Methods We retrospect…
View article: Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist?
Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist? Open
Esophageal cancer remains a challenging disease due to limited treatment options and poor prognosis. In recent years, immune checkpoint inhibitors (ICI) have been proven to be safe and effective in the treatment of highly lethal malignanci…
View article: ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer
ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer Open
View article: Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre
Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre Open
View article: Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study Open
Early tumor shrinkage (ETS) and depth of response (DoR) predict favorable outcomes in metastatic colorectal cancer. We aim to evaluate their prognostic role in metastatic pancreatic cancer (PC) patients treated with first-line modified-FOL…
View article: Longitudinal evaluation of angiogenesis-related circulating biomarkers during second-line treatment with paclitaxel and ramucirumab in advanced gastroesophageal cancer
Longitudinal evaluation of angiogenesis-related circulating biomarkers during second-line treatment with paclitaxel and ramucirumab in advanced gastroesophageal cancer Open
View article: Characterization of mismatch repair deficiency in biliary tract cancer
Characterization of mismatch repair deficiency in biliary tract cancer Open
View article: Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients Open
View article: Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of a Frail Route
Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of a Frail Route Open
Macarulla et al 1 have recently reported the results of a phase I/II trial (NAB-Paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer [FRAGANCE]) that explored the safest and most effective dose and…
View article: Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer Open
A simple nomogram based on always-available pathologic information accurately predicts the probability of HER2 positivity in GOC.
View article: Selective induction of PD-L1 expression in plasma-derived exosomes by gemcitabine-nab-paclitaxel vs. FOLFIRINOX in pancreas cancer
Selective induction of PD-L1 expression in plasma-derived exosomes by gemcitabine-nab-paclitaxel vs. FOLFIRINOX in pancreas cancer Open
View article: Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram
Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram Open
View article: Analysis of early tumor shrinkage and depth of response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or gemcitabine + nab-paclitaxel
Analysis of early tumor shrinkage and depth of response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or gemcitabine + nab-paclitaxel Open
Introduction: Early Tumor Shrinkage (ETS) and Depth of Response (DoR) can help in predicting favourable outcome in metastatic colorectal cancer. Combination chemotherapy such as FOLFIRINOX or gemcitabine+nab-paclitaxel (GemNab) represents …
View article: AB076. P048. Microsatellite instability and tumor volume inversely affect early progression free survival in adjuvant setting of patients with pancreatic ductal adenocarcinoma: lights and shadows of molecular pathology and immunotherapy
AB076. P048. Microsatellite instability and tumor volume inversely affect early progression free survival in adjuvant setting of patients with pancreatic ductal adenocarcinoma: lights and shadows of molecular pathology and immunotherapy Open
View article: First‐line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors
First‐line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors Open
FOLFIRINOX is a standard first‐line treatment for advanced pancreatic cancer (aPC). The Gruppo Oncologico Nord Ovest (GONO) FOLFOXIRI regimen demonstrated efficacy in metastatic colorectal cancer. We aimed to evaluate activity and tolerabi…
View article: Prognostic model for patients (pts) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (mFOLFIRINOX)
Prognostic model for patients (pts) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (mFOLFIRINOX) Open